Showing results (5481-5490 of 5,703) with videos related to

Sort By:
Pageof 571
The Oncologist|August 10, 2022
Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic CancerSatoshi Kobayashi, Motoko Suzuki, Makoto Ueno, et al.
The Oncologist|August 10, 2022
The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final ResultsTetsuji Terazawa, Takeshi Kato, Masahiro Goto, et al.
The Oncologist|August 10, 2022
Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin LymphomaDeepa Jagadeesh, Steve Horwitz, Nancy L Bartlett, et al.
The Oncologist|August 3, 2022
Five-Year Prospective Observational Study of African-American Men on Active Surveillance for Prostate Cancer Demonstrates Race Is Not Predictive of Oncologic OutcomesJoshua Pincus, Jacob W Greenberg, Caleb Natale, et al.
The Oncologist|August 3, 2022
Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with AngiosarcomaRichard F Riedel, Victoria Chua, Ania Moradkhani, et al.
The Oncologist|May 27, 2020
A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic AdenocarcinomaMarc T Roth, Dana Backlund Cardin, Erkut Hasan Borazanci, et al.
The Oncologist|May 6, 2021
The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint InhibitorsSaby George, Elizabeth J Bell, Ying Zheng, et al.
The Oncologist|May 10, 2021
Moral Distress and Resilience Associated with Cancer Care Priority Setting in a Resource-Limited ContextRebecca J DeBoer, Espérance Mutoniwase, Cam Nguyen, et al.
The Oncologist|June 12, 2020
Neurological and Dexterity Assessments in a Woman with Radiation-Induced Brachial Plexopathy After Breast CancerSusan R Harris, Karen E Tugwell
The Oncologist|June 4, 2020
Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung CancerMohammad Jahanzeb, Huamao M Lin, Xiaoyun Pan, et al.
Pageof 571